Hypoxia-Targeting Carbonic Anhydrase IX Inhibitors by a New Series of Nitroimidazole-Sulfonamides/Sulfamides/Sulfamates

Marouan Rami, Ludwig Dubois, Nanda-Kumar Parvathaneni, Vincenzo Alterio, Simon J. A. van Kuijk, Simona Maria Monti, Philippe Lambin, Giuseppina De Simone, Claudiu T. Supuran, Jean-Yves Winum*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

78 Downloads (Pure)


A series of nitroimidazoles incorporating sulfonamide/sulfamide/sulfamate moieties were designed and synthesized as radio/chemosensitizing agent targeting the tumor-associated carbonic anhydrase (CA) isoforms IX and XII. Most of the new compounds were nanomolar inhibitors of these isoforms. Crystallographic studies on the complex of hCA II with the lead sulfamide derivative of this series clarified the binding mode of this type of inhibitors in the enzyme active site cavity. Some of the best nitroimidazole CA IX inhibitors showed significant activity in vitro by reducing hypoxia-induced extracellular acidosis in HT-29 and HeLa cell lines. In vivo testing of the lead molecule in the sulfamide series, in cotreatment with doxorubicin, demonstrated a chemosensitization of CA IX containing tumors. Such CA inhibitors, specifically targeting the tumor-associated isoforrns, are candidates for novel treatment strategies against hypoxic tumors overexpressing extracellular CA isozymes.
Original languageEnglish
Pages (from-to)8512-8520
JournalJournal of Medicinal Chemistry
Issue number21
Publication statusPublished - 14 Nov 2013


Dive into the research topics of 'Hypoxia-Targeting Carbonic Anhydrase IX Inhibitors by a New Series of Nitroimidazole-Sulfonamides/Sulfamides/Sulfamates'. Together they form a unique fingerprint.

Cite this